Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu; "Sysmex") will present one poster showing the most recent data on using blood as a method of diagnosing Alzheimer’s disease at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference, held virtually from November 4 to 7, 2020. Sysmex is conducting this development in collaboration with Eisai Co., Ltd. (HQ: Tokyo, Japan; CEO: Haruo Naito; "Eisai").
In February 2016, Sysmex and Eisai signed a non-exclusive comprehensive agreement aimed at the creation of new diagnostics in the field of dementia. By leveraging each other’s technologies and knowledge, we aim to discover next-generation diagnostic drugs that will enable early diagnosis, selection of the treatment options and the regular monitoring of the effects of treatment for dementia.
Sysmex and Eisai are pursuing joint development aimed at creating a simple method of diagnosing Alzheimer’s disease using blood. At CTAD, Sysmex will announce the most recent data produced by an automated protein assay system using its protein measurement platform, the HISCLTM fully automated immunoassay system.
Clinical trials: biomarkers including plasmaLP10
Plasma Aβ ratio measured on a fully automated immunoassay predicts amyloid positivity defined by amyloid PET centiloidPoster presentation: November 4 (Wed.) to November 7 (Sat.)
Sysmex is working to create new diagnostic technologies for the prevention and treatment of dementia. As a result, we aim to contribute to the advancement of healthcare and improve the quality of life for patients and their families.
Information contained in the press release is current as of the date of the announcement but may be subject to change without prior notice.